Belite Bio Seeks First-Ever Stargardt Disease Treatment Approval in Three Markets

  • Belite Bio submits Marketing Authorization Applications for tinlarebant in Singapore, UK, and Switzerland via Access Consortium pathway
  • Tinlarebant could become the first approved treatment for Stargardt Disease Type 1 in these markets if approved
  • U.S. NDA submission under Priority Review with PDUFA target action date of February 12, 2027
  • Japan submission under SAKIGAKE Designation System for accelerated review
  • Phase 3 DRAGON trial for STGD1 met primary endpoint, Phase 2/3 DRAGON II and Phase 3 PHOENIX trials ongoing

Belite Bio's multi-market regulatory strategy positions tinlarebant as a potential first-in-class treatment for Stargardt Disease Type 1. The company's parallel submissions via the Access Consortium and existing filings in major markets demonstrate a coordinated global approach. Success would establish Belite Bio as a leader in retinal disease therapeutics, with potential to expand into geographic atrophy treatment.

Regulatory Timelines
Whether the Access Consortium pathway will accelerate approval processes in Singapore, UK, and Switzerland compared to traditional routes
Commercialization Strategy
How Belite Bio plans to build commercial infrastructure for potential global launch of tinlarebant
Clinical Pipeline
Progress of ongoing Phase 2/3 DRAGON II and Phase 3 PHOENIX trials and their potential impact on regulatory decisions